S&P Futures
4,079.75 -10.25 (-0.25%) Dow Futures
34,019.00 -137.00 (-0.40%) Nasdaq Futures
12,142.50 -9.50 (-0.08%) Russell 2000 Futures
1,935.30 -4.10 (-0.21%) Crude Oil
79.26 +0.39 (+0.49%) Gold
1,944.60 -0.70 (-0.04%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 31.70 |
| Open | 32.43 |
| Bid | 32.27 x 800 |
| Ask | 33.52 x 800 |
| Day's Range | 31.93 - 33.03 |
| 52 Week Range | 19.35 - 35.92 |
| Volume | |
| Avg. Volume | 343,658 |
| Market Cap | 1.925B |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.21 |
| Earnings Date | Feb 21, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 48.25 |
- Motley Fool
Why Shares of Zencor Rose This Week
Shares of Xencor (NASDAQ: XNCR) rose 12.6% this week as of Thursday afternoon, according to data provided by S&P Global Market Intelligence. The stock closed at $28.83 on Friday and then rose as high as $33.06 on Thursday. Xencor stock was up as high as 14.7% for the week before falling a bit later in the day Thursday.
- Business Wire
Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates
MONROVIA, Calif., January 09, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.
- PR Newswire
Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates
Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced an expansion of their collaboration to research, develop and commercialize novel XmAb® bispecific and multi-specific antibodies directed agai
